WntResearch: Nils Brünner steps up as new CEO

Chairman of the Board Peter Buhl Jensen comments:
I'm very happy that Professor Brünner has accepted the position as a CEO of the Company. Dr. Nils Brünner is a highly respected and world class oncology specialist with an international network which is of huge value to the Company. Brünner serves the advisory role in several biotech and big diagnostic companies and in key organizations in the international oncology community and has many years of successful experience as an innovative leader. Professor Brünner has been scientific advisor to WntResearch since 2008. I look forward to our future collaboration that will focus on the creation of value to the shareholders by optimizing the clinical development of Foxy-5 for the treatment of metastatic cancer and on building partnerships.

I'm grateful to Bert Junno who successfully led WntResearch from a small spin-out company from Lund University to a listed public company on AktieTorget and welcomes Bert in his new position as CFO of WntResearch.




For further information please contact:
Peter Buhl Jensen, Chairman of the Board
E-mail: pbj@buhloncology.com
Telephone: +45 2160 8922


View news item from WntResearch: //WWW03/Press/Wntresearch/60781/WntResearch_WNT_20120112_8.pdf